

NATUS MEDICAL INC  
Form 8-K  
December 27, 2013  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 OR 15(d) of**  
**The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 27, 2013

Natus Medical Incorporated  
(Exact name of registrant as specified in its charter)

|   |                             |                                      |
|---|-----------------------------|--------------------------------------|
| Delaware  | 000-33001                   | 77-0154833                           |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

1501 Industrial Road, San Carlos, California 94070  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (650) 802-0400

Not applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

At its December 27, 2013 meeting, the Compensation Committee of the Board of Directors of Natus Medical Incorporated (the "Company") approved the base salaries and bonus program for the Company's named executive officers (NEO) for the period beginning January 1, 2014 and ending December 31, 2014. In addition, the Compensation Committee elected to change the date of the 2014 equity awards from the middle of the year, as had been done in the past, to the beginning of the year.

The Compensation Committee approved the base annual salary amounts set forth in the table below:

| <u>NEO</u>  | <u>Salary</u> |
|---|---------------|
| James B. Hawkins<br><i>President &amp; Chief Executive Officer</i>                          | \$ 650,000    |
| Jonathan A. Kennedy<br><i>Sr. Vice President Finance &amp; Chief Financial Officer</i>      | \$ 380,000    |
| Austin F. Noll, III<br><i>Vice President and General Manager, Neurology</i>                 | \$ 295,000    |
| Kenneth M. Traverso<br><i>Vice President and General Manager, Newborn Care</i>              | \$ 295,000    |
| D. Christopher Chung, M.D.<br><i>Vice President Medical Affairs, Quality and Regulatory</i> | \$ 267,000    |

The Compensation Committee also approved a cash bonus plan for executive officers of the Company for 2014. Cash bonuses may range from 50% to a maximum of 200% of the target amount.

The target bonus as a percentage of 2014 base salary is 100% for Mr. Hawkins, 65% for Mr. Kennedy, 50% for each of Messrs. Noll and Traverso, and 40% for Dr. Chung.

The target bonus is based on achievement of the following goals and weighting:

| NEO         | Minimum Threshold  | Consolidated Revenue | Consolidated Pre-Tax Earnings | Specific Strategic Objectives | Business Unit Revenue | Business Unit Profitability |
|-------------|--|----------------------|-------------------------------|-------------------------------|-----------------------|-----------------------------|
| Mr. Hawkins | Achieve at least 80% of consolidated pre-tax income contained in the 2014 Plan | 20%                  | 80%                           | --                            | --                    | --                          |
| Mr. Kennedy |  | 15%                  | 15%                           | 20%                           | 25%                   | 25%                         |
| Mr. Noll    |  |                      |                               |                               |                       |                             |



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NATUS MEDICAL  
INCORPORATED

**Date:** December 27, 2013    **By:** /s/ Jonathan A. Kennedy  
**Jonathan A. Kennedy**  
Sr. Vice President and  
Chief Financial Officer